Stock · BSX · Healthcare
United States · Large Cap · listed since 1992 · Revenue 12 mo. $21B
Price as of 11/06/2026
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Original text from the data provider
Summary
45.1 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €3.3B (2025), it supports €36.5B. The remaining €16.2B of the market value assume it grows 5.2% a year for 10 years and not at all afterwards.
Required FCF growth per year
5.2%
no growth afterwards
Price to operating cash flow 14.0×, below its usual range.
Middle half of 20 quarters: 32.4× to 41.9×, median 38.1×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., Gross margin, FCF margin, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 11.91% | 11.52% | Rank 53 |
| Return on capital (Greenblatt) | 50.55% | 32.55% | Rank 69 |
| EBIT margin | 19.78% | 18.31% | Rank 59 |
| FCF margin | 18.22% | 14.12% | Rank 65 |
| Gross margin | 69.01% | 60.99% | Rank 63 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 19.87% | 8.04% | Rank 84 |
| Earnings growth, 3 years per year | 58.52% | 5.44% | Rank 93 |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 4.36% | 3.66% | Rank 56 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.52% | 2.90% | Rank 74 |
| FCF yield | 6.23% | 3.63% | Rank 82 |
| EV/saleslower is better | 3.44 | 4.03 | Rank 55 |
| EV/EBITlower is better | 17.39 | 21.73 | Rank 68 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −66.45% | 8.66% | Rank 1 |
| Share price, 6 months | −20.25% | 24.27% | Rank 3 |
| Share price, 3 months | −8.17% | 15.42% | Rank 3 |
| Distance from 52-week high | −59.28% | −7.35% | Rank 2 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 2.39% | 0.30% | Rank 31 |
| Change in share countlower is better | 0.58% | 0.00% | Rank 19 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −6.07% | 0.05% | Rank 8 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 55.49% | 48.40% | Rank 62 |
| Net debt/EBITDAlower is better | 2.03 | 1.11 | Rank 29 |
| Debt to equitylower is better | 0.51 | 0.48 | Rank 49 |
| Volatility, 1 yearlower is better | 39.26% | 31.42% | Rank 28 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 8.4 | 14.7% | $596.0M | 1.38B | 5.3 |
| 2017 | 9.0 | 16.9% | $1.1B | 1.39B | 5.4 |
| 2018 | 9.8 | 17.7% | −$6.0M | 1.40B | 6.9 |
| 2019 | 10.7 | 16.0% | $1.4B | 1.41B | 10.1 |
| 2020 | 9.9 | 6.1% | $1.1B | 1.42B | 7.8 |
| 2021 | 11.9 | 16.2% | $1.3B | 1.43B | 7.5 |
| 2022 | 12.7 | 14.4% | $914.0M | 1.44B | 8.4 |
| 2023 | 14.2 | 15.3% | $1.7B | 1.46B | 8.6 |
| 2024 | 16.7 | 15.7% | $2.6B | 1.49B | 10.7 |
| 2025 | 20.1 | 19.8% | $3.7B | 1.49B | 10.4 |
6 of 7 StockScorer Score rules met · How the score is built
Boston Scientific Corp mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Boston Scientific Corp is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
6 of 7 rules met
10 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Boston Scientific Corp.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 22.1 | 30.0 |
| P/B ratio | 2.6 | 4.8 |
| Return on equity (ROE) | 11.9% | 11.5% |
| Equity ratio | 55.5% | 48.4% |
| Debt-to-equity (D/E) | 0.51 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| BSX | Boston Scientific Corpthis page | |
| EW | Edwards Lifesciences Corp | Low1.8 |
| GEHC | GE HealthCare Technologies Inc. | Low4.5 |
| DXCM | DexCom Inc | High8.2 |
| STE | STERIS plc | locked |
| ZBH | Zimmer Biomet Holdings Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.